Baxdrostat vs QLS1410
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca and partners
NCT06034743 · Phase 3 · completed
The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
Reported efficacy
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy (Baseline to week 12): Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). (met)
Result source: NCT06168409
QLS1410
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07489612 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Baxdrostat | QLS1410 |
|---|---|---|
| Seated SBP, change | -15.7 vs -5.8−9.9 vs placeboNCT060347437 other results
| —Not reported |
| 24-hour ambulatory SBP, change | -16.6 vs -2.6−14 vs placeboNCT06168409 | —Not reported |
| Seated DBP, change | -6.9 vs -3−3.9 vs placeboNCT060347434 other results
| —Not reported |
Seated SBP, change
- Baxdrostat
- -15.7 vs -5.8−9.9 vs placeboNCT06034743
7 other results
- -14.5 vs -5.8 NCT06034743
- -3.7 vs 1.4 NCT06034743
- -15.2 vs -5.4 NCT06034743
- -14.9 vs -4.7 NCT06168409
- -11.6 vs -2.4 NCT06168409
- -12.1 vs -1.1 NCT06168409
- -14.5 vs -5.4 NCT06034743
- QLS1410
- —Not reported
24-hour ambulatory SBP, change
- Baxdrostat
- -16.6 vs -2.6−14 vs placeboNCT06168409
- QLS1410
- —Not reported
Seated DBP, change
- Baxdrostat
- -6.9 vs -3−3.9 vs placeboNCT06034743
4 other results
- -7.6 vs -2.6 NCT06168409
- -6.1 vs -0.5 NCT06168409
- -5.4 vs 0.1 NCT06168409
- -6.3 vs -3 NCT06034743
- QLS1410
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QLS1410: no structured comparison results are available for Hypertension.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Baxdrostat: 3 of 4 rows · QLS1410: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Baxdrostat |
|---|---|
| Dropout rate | 10.9%2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results—2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 7.2%1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 5.5%2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 6.3%2 mg NCT06336356 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results—2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06336356 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.4%2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results2.3%2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 4.8%2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 1.9%1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 0.9%2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 0%2 mg NCT06336356 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 2 mga hyperkalaemia 11.7% (placebo 2.7%) hyponatraemia 3.8% (placebo 0.8%) muscle spasms 3.8% (placebo 0.4%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results2 mg hyperkalaemia 9.9% (placebo 2.7%) hyponatraemia 3.5% (placebo 0.8%) nasopharyngitis 1.7% (placebo 2.3%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg hyperkalaemia 16.1% (placebo 2.7%) hyponatraemia 11.3% (placebo 0.8%) muscle spasms 6.5% (placebo 0.4%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 1 mg hyperkalaemia 6.1% (placebo 2.7%) nasopharyngitis 3% (placebo 2.3%) upper respiratory tract infection 2.7% (placebo 3.8%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg hyperkalaemia 10.2% (placebo 2.8%) headache 5.6% (placebo 2.8%) hypotension 4.6% (placebo 0%) NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg dizziness 6.3% (placebo 6.3%) nausea 6.3% (placebo 0%) vomiting 6.3% (placebo 0%) NCT06336356 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Baxdrostat
show 7 more results
show 4 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · QLS1410's landscape